Published On: Wed, Oct 19th, 2016

Broker Changes For Jazz Pharmaceuticals Plc (NASDAQ:JAZZ)


Recently stock market analysts have updated their consensus ratings on shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ).

Most recent broker ratings

10/05/2016 – Jazz Pharmaceuticals plc had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 195 price target on the stock.

09/27/2016 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at Goldman Sachs. They now have a USD 187 price target on the stock.

09/21/2016 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at UBS. They now have a USD 168 price target on the stock.

09/15/2016 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at Mizuho. They now have a USD 185 price target on the stock.

09/06/2016 – Jazz Pharmaceuticals plc had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 202 price target on the stock.

08/25/2016 – Janney Montgomery Scott began new coverage on Jazz Pharmaceuticals plc giving the company a “neutral” rating.

08/11/2016 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at Deutsche Bank. They now have a USD 158 price target on the stock.

08/10/2016 – Jazz Pharmaceuticals plc had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 178 price target on the stock.

06/02/2016 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at SunTrust. They now have a USD 210 price target on the stock.

03/31/2016 – Jazz Pharmaceuticals plc had its “outperform” rating reiterated by analysts at Northland Securities. They now have a USD 175 price target on the stock.

02/24/2016 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 200 price target on the stock.

02/19/2016 – Wells Fargo began new coverage on Jazz Pharmaceuticals plc giving the company a “outperform” rating.

11/25/2015 – Sanford C. Bernstein began new coverage on Jazz Pharmaceuticals plc giving the company a “market perform” rating. They now have a USD 160 price target on the stock.

11/10/2015 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at Cowen.

11/10/2015 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 170 price target on the stock.

Jazz Pharmaceuticals plc has a 50 day moving average of 123.14 and a 200 day moving average of 139.48. The stock’s market capitalization is 7.22B, it has a 52-week low of 108.50 and a 52-week high of 160.00.

The share price of the company (NASDAQ:JAZZ) was up +1.41% during the last trading session, with a high of 120.14 and the volume of Jazz Pharmaceuticals plc shares traded was 281548.